Acerus Pharmaceuticals Corporation reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 0.587 million compared to USD 0.493 million a year ago. Net loss was USD 4.9 million compared to USD 7.05 million a year ago.
For the nine months, negative revenue was USD 4.87 million compared to revenue of USD 0.814 million a year ago. Net loss was USD 24.79 million compared to USD 17.32 million a year ago. Basic loss per share from continuing operations was USD 4 compared to USD 4 a year ago. Diluted loss per share from continuing operations was USD 4 compared to USD 4 a year ago.